Form 3 January 02, 2018						
FORM 3 UNITED STA		ID EXCHANGE COMMISS	SION	OMB AI	PPROVAL	
	Washington, I	D.C. 20549		OMB Number:	3235-0104	4
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES			Expires:	January 31 2005		
Filed pursuant	Estimated average burden hours per response		5			
	the Public Utility Holdi 0(h) of the Investment C	ng Company Act of 1935 or S Company Act of 1940	Section	l		
(Print or Type Responses)						
1. Name and Address of Reporting Person <u>*</u> Suesskind Dan S	2. Date of Event Requiring Statement (Month/Day/Year) 01/01/2018 3. Issuer Name and Ticker or Trading Symbol TEVA PHARMACEUTICAL INDU [TEVA]				LTD	
(Last) (First) (Middle)	01/01/2018	4. Relationship of Reporting Person(s) to Issuer		Amendment, D Month/Day/Yea	e	
C/O TEVA PHARMACEUTICAL		(Check all applicable)		ĩ		
INDUSTRIES LTD., 5 BASEL STREET		_X_Director10% Owner OfficerOther				
(Street)		(give title below) (specify below)	6. Indi	ividual or Join	t/Group	
РЕТАСН			_X_ Fo Person		e Reporting	
TIKVA, L3 4951033				rm filed by Mor ing Person		
(City) (State) (Zip)	Table I - N	Non-Derivative Securities Be	eneficia	ally Owned	I	
1.Title of Security	2. Amount o	f Securities 3. 4. Na	ture of I	Indirect Benef	icial	

1.Title of Security (Instr. 4)

Suesskind Dan S

Ordinary Shares (1)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

Beneficially Owned

(Instr. 4)

299,136

Ownership

Direct (D) or Indirect (I) (Instr. 5) D

SEC 1473 (7-02)

Form:

Ownership

(Instr. 5)

Â

1. Title of Derivative Security	2. Date Exercisable and	3. Title and Amount of	4.	5.	6. Nature of Indirect
(Instr. 4)	Expiration Date	Securities Underlying	Conversion	Ownership	Beneficial Ownership
	(Month/Day/Year)	Derivative Security	or Exercise	Form of	(Instr. 5)

Edgar Filing: Suesskind Dan S - Form 3

	Date Exercisable	Expiration Date	(Instr. 4) Title	Amount or Number of Shares	Price of Derivative Security	Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	
Restricted Share Units	(2)	(2)	Ordinary Shares (1)	9,575	\$ <u>(3)</u>	D	Â

Reporting Owners

Reporting Owner Name / Address		Relationships				
		10% Owner	Officer	Other		
Suesskind Dan S C/O TEVA PHARMACEUTICAL INDUSTRIES LTD. 5 BASEL STREET PETACH TIKVA, L3 4951033	ÂX	Â	Â	Â		
Signatures						
/s/ Dov Bergwerk, as attorney-in-fact for Dan S. Suesskind		/02/2018				
**Signature of Reporting Person		Date				

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).

- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- (2) Restricted share units were granted on November 10, 2017 and vest on November 10, 2020.
- (3) Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Â

Remarks:

The Reporting Person is filing this form in connection with the Issuer's transition from a foreign p

Exhibit List

Â Â Â Â Ê xhibit 24 - Power of Attorney

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.